Successful Treatment of Abdominal Wall Advanced Endometriosis-Associated Clear Cell Carcinoma
Author Information
Author(s): Ko Ya-Ting, Wu Ching-Hsuan, Chang Cheng-Shyong, Lai De-Wei, Liu Ta-Chih
Primary Institution: Chang Bing Show Chwan Memorial Hospital
Hypothesis
Can AKT pathway inhibitors effectively treat endometriosis-associated clear cell carcinoma?
Conclusion
The combination of alpelisib and everolimus led to a sustained complete response in a patient with endometriosis-associated clear cell carcinoma.
Supporting Evidence
- The patient had a sustained complete response after treatment with alpelisib and everolimus.
- Next-generation sequencing identified a targetable PIK3CA E726K mutation.
- The patient experienced manageable side effects during treatment.
Takeaway
A woman with a rare type of cancer related to endometriosis was treated successfully with special medicines that target cancer pathways.
Methodology
The patient underwent surgical resection followed by chemotherapy, radiotherapy, immunotherapy, and targeted therapy, with next-generation sequencing used to identify mutations.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
The patient was a 50-year-old woman with no previous history of cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website